Cytosar-U, Cytarabine News

A targeted drug that is active against acute myeloid leukemia is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's annual meeting on Monday, Dec.

Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Cancer / Oncology Clavis Pharma ASA announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia was presented at the 51st American Society of Hematology Annual Meeting in New ...

LONDON and CAMBRIDGE, MA, and NEW ORLEANS, LA -- -- 12/07/09 -- Antisoma plc announces that positive final data from a phase II trial of AS1413 in patients with secondary acute myeloid leukaemia were presented this weekend at the American Society of Hematology meeting in New Orleans.

Lorus Therapeutics Announces Positive Result In Its Phase II Clinical Study Of LOR-2040 In Acute Myeloid Leukemia Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Cancer / Oncology Clinical Trials / Drug Trials Lorus Therapeutics Inc.

The study, entitled "An Open-Label Randomised Phase II Study of the X-Linked Inhibitor of Apoptosis Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen", is being conducted in the United States and Canada and will also be ...

Antisoma plc holds its AGM today and provides an update, which also serves as the Company's Interim Management Statement for the period from 1 July 2009 to 9 November 2009.

Fotemustine plus etoposide, cytarabine and melphalan as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study 1Department of Oncology, Oncohematology and Bone Marrow Transplantation Unit, 'La Maddalena', Palermo, Italy 2Hematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, ...

South San Francisco-based Sunesis is conducting two Phase 2 clinical trials of voreloxin with newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine.

Subsequently, he developed fever, progressive lung infiltrates, and severe neutropenia.

Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Pharma Industry / Biotech Industry Sunesis Pharmaceuticals, Inc.

Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Pharma Industry / Biotech Industry Celator Pharmaceuticals announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 Liposome Injection versus conventional cytarabine and daunorubicin therapy in patients 60-75 years of age ...

Antisoma has announced that, following discussions with FDA and trial investigators, it plans to amend the primary endpoint in the ACCEDE study of AS1413.

However, studies at single institutions have suggested that 55 to 65 percent of such patients might be cured by third-generation regimens such as ones consisting of low-dose methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone ; prednisone, doxorubicin, cyclophosphamide, and etoposide, ...

The addition of high-dose cytarabine to standard methotrexate treatment of primary central nervous system lymphomas greatly improves remission rates, according to a study published early online Sept.

Hugo F. Fernandez, M.D., Zhuoxin Sun, Ph.D., Xiaopan Yao, Ph.D., Mark R. Litzow, M.D., Selina M. Luger, M.D., Elisabeth M. Paietta, Ph.D., Janis Racevskis, Ph.D., Gordon W. Dewald, Ph.D., Rhett P. Ketterling, M.D., John M. Bennett, M.D., Jacob M. Rowe, M.D., Hillard M. Lazarus, M.D., and Martin S. Tallman, M.D. ABSTRACT Background In young adults ...

Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Cancer / Oncology Combining cytarabine with conventional monochemotherapy improves remission rates in patients with primary central nervous system lymphoma.

President Gloria Arroyo signed on Monday an executive order that would impose a mandatory 50-percent decrease in the prices of five essential medicines after drug companies refused the voluntary reduction of their prices.

The Philippines ordered a 50 percent price cut on five key drugs after pharmaceutical companies failed to lower the prices on their own, officials said Tuesday.

Celator Pharmaceuticals today announced that new clinical and preclinical data demonstrating the extended therapeutic bioavailability and tumor cell selectivity of CPX-351 Liposome Injection in leukemia were presented at the 14th Congress of the European Hematology Association in Berlin, Germany, June 4-7, 2009 .

Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro.